Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine.

ABSTRACT:

SUBMITTER: Rosen N 

PROVIDER: S-EPMC6594135 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature